Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10304843 | 0.86 | TTR (0.33) | ACHE | |
| SCHEMBL16527152 | 0.86 | TTR (0.33) | ACHE | |
| SCHEMBL12583448 | 0.80 | TTR (0.33) | ACHE | |
| SCHEMBL22597911 | 0.79 | ALDH1A1 (0.39) | RAPGEF4 | |
| SCHEMBL22719596 | 0.79 | KDM1A (0.41) | — | |
| SCHEMBL23706706 | 0.79 | CA3 (0.36) | — | |
| SCHEMBL848915 | 0.79 | CYP3A4 (0.40) | — | |
| SCHEMBL32665527 | 0.79 | KDM4E (0.37) | — | |
| SCHEMBL16656287 | 0.78 | RXRA (0.30) | — | |
| SCHEMBL4138790 | 0.77 | GPR84 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| WO-2021181416-A1 | PROCESS FOR THE PREPARATION OF 1-BROMO-2,4,5-TRIFLUOROBENZENE | AARTI INDUSTRIES LIMITED (IN) | 2021-09-16 | — | — | WO | disclosed |
| EP-3194385-B3 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | CHRONOS THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020038458-A1 | CLASS OF FUSED RING TRIAZOLE COMPOUND, PREPARATION METHOD, AND USE | 如东凌达生物医药科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | ACHE 4807/4885RAPGEF4 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.